AB ScienceABSCF 58 PS Ratio is 50.91 as of Jul. 05, 2026, which is 73% below its 10-year median of 188.43. GuruFocus rates ABSCF with a GF Score™ of 58/100 and a GF Value™ of $2.13 (Modestly Undervalued). The stock has 11 warning signs investors should review. Among 949 Drug Manufacturers companies, AB Science ranks worse than 96.31% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, AB Science's share price is $1.12.
AB Science's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was $0.02. Hence, AB Science's PS Ratio for today is 50.91.
Good Sign:
AB Science stock PS Ratio (=40.68) is close to 10-year low of 40.68.
The historical rank and industry rank for AB Science's PS Ratio or its related term are showing as below:
ABSCF'
s PS Ratio Range Over the Past 10 Years
Min: 40.68 Med: 188.43 Max: 546.11
Current: 40.68
During the past 13 years, AB Science's highest PS Ratio was 546.11. The lowest was 40.68. And the median was 188.43.
ABSCF's PS Ratio is ranked worse than 96.31% of 949
companies
in the Drug Manufacturers industry
Industry Median: 2.31
vs ABSCF: 40.68
AB Science revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue per Share Growth Rate of AB Science was -5.00% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 8.20% per year.
During the past 5 years, the average Revenue per Share Growth Rate was -10.60% per year.
During the past 10 years, the average Revenue per Share Growth Rate was -13.30% per year.
During the past 13 years, AB Science's highest 3-Year average Revenue per Share Growth Rate was 56.30% per year. The lowest was -27.90% per year. And the median was -8.15% per year.
Back to Basics: PS Ratio
AB Science (OTCPK:ABSCF) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
AB Science PS Ratio Related Terms
AB Science PS Ratio Historical Data
* Premium members only.
The historical data trend for AB Science's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, AB Science's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AB Science PS Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, AB Science's PS Ratio distribution charts can be found below:
* The bar in red indicates where AB Science's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
AB Science's Share Price of today is $1.12.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. AB Science's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was $0.02.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
AB Science (ABSCF) has a PS Ratio of 50.91 as of Jul. 05, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on AB Science and its competitors. This is 73% below median its historical median of 188.43. Over the past decade, AB Science's PS Ratio has ranged from 40.68 to 546.11. According to the industry distribution chart, AB Science ranks #914 out of 949 companies in the Drug Manufacturers industry, placing it in the top 96.3%.
Is AB Science's PS Ratio too high?
AB Science's current PS Ratio of 50.91 is 73% below median its 10-year median of 188.43. Over the past 10 years, this metric has ranged from a low of 40.68 to a high of 546.11. The Drug Manufacturers industry median PS Ratio is 2.31. AB Science's value of 50.91 is 2103.9% above this industry median. Based on the distribution chart, AB Science ranks #914 out of 949 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, AB Science has a GF Score™ of 58/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does AB Science's PS Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, AB Science ranks #914 out of 949 companies for PS Ratio. This places AB Science in the lower half of its industry. The industry median PS Ratio is 2.31. AB Science's value of 50.91 is 2103.9% above this benchmark. Historically, AB Science's own PS Ratio has ranged from 40.68 to 546.11 over the past decade. While the company's 10-year median is 188.43 vs. the industry median of 2.31, AB Science has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Drug Manufacturers company?
The median PS Ratio among Drug Manufacturers companies is 2.31, based on 949 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. AB Science's current PS Ratio of 50.91 is 2103.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on AB Science and its competitors. For the Drug Manufacturers industry, the median PS Ratio is 2.31 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AB Science's current PS Ratio is 50.91, which is 73% below median its own 10-year median of 188.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AB Science stock overvalued right now?
Based on GuruFocus' analysis, AB Science (ABSCF) is currently considered Modestly Undervalued. The stock's GF Value™ is $2.13, compared to a current price of $1.12 — trading 47.4% below its estimated fair value. The current PS Ratio is 50.91, which is 73% below median its 10-year median of 188.43 and 2103.9% above the Drug Manufacturers industry median of 2.31. AB Science's overall GF Score™ is 58/100 with 11 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For AB Science (ABSCF), the current PS Ratio is 50.91 as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is AB Science (ABSCF) Overvalued in 2026?
Based on GuruFocus' analysis, AB Science stock appears to be undervalued.
The current stock price of $1.12 is trading 47.4% below its estimated GF Value™ of $2.13.
GuruFocus considers AB Science to be Modestly Undervalued.
Key valuation signals for ABSCF:
PS Ratio: 50.91 (73% below median its 10-year median of 188.43)
GF Value™: $2.13 vs. price of $1.12 (47.4% below fair value)
Industry Position: 2103.9% above the Drug Manufacturers median (#914 of 949)
No single metric tells the full story. See the ABSCF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
AB Science is a clinical-stage pharmaceutical company that has developed a diversified portfolio of medicines targeting unmet medical needs, based on two platforms. Masitinib platform: It is based on masitinib, a selective protein kinase inhibitor in development for neurodegenerative diseases, oncology, & inflammatory diseases. It has the clinical development of masitinib in neurodegenerative diseases (specifically Alzheimer's disease, amyotrophic lateral sclerosis, & progressive forms of multiple sclerosis). ALDH/Microtubule Platform: It is a portfolio of synthetic agents that target cancer cells by destabilising microtubules, which are essential for cell division & cancer stem cells, by inhibiting enzymes that are essential for maintaining their physiological state & survival.
58GF Score
Get the complete analysis for ABSCF
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ABSCF has been successfully added to your 
